Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2001-03-26
2009-12-22
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S191100, C424S192100
Reexamination Certificate
active
07635479
ABSTRACT:
Compositions and methods for enhancing the immunogenicity of an antigen via fusion to a non-hemolytic truncated form of listeriolysin or a PEST-like amino acid sequence derived from a prokaryotic organism are provided.
REFERENCES:
patent: 4521382 (1985-06-01), Kessick
patent: 4567041 (1986-01-01), Likhite
patent: 4777239 (1988-10-01), Schoolnik et al.
patent: 4816253 (1989-03-01), Likhite et al.
patent: 4879213 (1989-11-01), Fox et al.
patent: 5262177 (1993-11-01), Brown et al.
patent: 5342774 (1994-08-01), Boon et al.
patent: 5369008 (1994-11-01), Arilnghause et al.
patent: 5643599 (1997-07-01), Lee et al.
patent: 5681570 (1997-10-01), Yang et al.
patent: 5824538 (1998-10-01), Branstrom et al.
patent: 5830702 (1998-11-01), Portnoy et al.
patent: 5858682 (1999-01-01), Gruenwald et al.
patent: 5876735 (1999-03-01), Reed
patent: 5877159 (1999-03-01), Powell et al.
patent: 6015567 (2000-01-01), Hudziak et al.
patent: 6051237 (2000-04-01), Paterson
patent: 6306404 (2001-10-01), LaPosta et al.
patent: 6333169 (2001-12-01), Hudziak et al.
patent: 6479258 (2002-11-01), Short
patent: 6521449 (2003-02-01), Polack et al.
patent: 6565852 (2003-05-01), Paterson
patent: 6767542 (2004-07-01), Paterson et al.
patent: 6855320 (2005-02-01), Paterson
patent: 7135188 (2006-11-01), Paterson
patent: 2003/0028206 (2003-02-01), Shiber
patent: 2003/0202985 (2003-10-01), Paterson
patent: 2003/0220239 (2003-11-01), Simard et al.
patent: 2004/0228877 (2004-11-01), Dubensky et al.
patent: 2005/0118184 (2005-06-01), Paterson et al.
patent: 2005/0129715 (2005-06-01), Paterson et al.
patent: 2006/0051380 (2006-03-01), Schulick et al.
patent: 2006/0093582 (2006-05-01), Paterson et al.
patent: 2006/0104991 (2006-05-01), Paterson et al.
patent: 2006/0121053 (2006-06-01), Sweeney et al.
patent: 2006/0205067 (2006-09-01), Paterson et al.
patent: 2006/0210540 (2006-09-01), Paterson et al.
patent: 2006/0233835 (2006-10-01), Paterson et al.
patent: 2006/0269561 (2006-11-01), Paterson et al.
patent: 2008/0124354 (2008-05-01), Paterson et al.
patent: 0 902 086 (1999-03-01), None
patent: 01 178592 (1989-07-01), None
patent: WO 90/12594 (1990-11-01), None
patent: WO 92/20356 (1992-11-01), None
patent: WO 93/15212 (1993-08-01), None
patent: WO 94/17192 (1994-08-01), None
patent: WO 96/14087 (1996-05-01), None
patent: WO 96/34631 (1996-11-01), None
patent: WO 98/48026 (1998-10-01), None
patent: WO 99/06544 (1999-02-01), None
patent: WO 99/07861 (1999-02-01), None
patent: WO 99/10496 (1999-04-01), None
patent: WO 99/25376 (1999-05-01), None
patent: WO 01/27295 (2001-04-01), None
patent: WO 01/72329 (2001-10-01), None
patent: WO 03/015716 (2003-02-01), None
patent: WO 03/092600 (2003-11-01), None
patent: WO 2004/006837 (2004-01-01), None
patent: WO 2006/036550 (2006-04-01), None
patent: WO 2007/061848 (2007-05-01), None
patent: WO 2007/106476 (2007-09-01), None
patent: WO 2007/130455 (2007-11-01), None
Decatur et al, Science 290: 992-995, Nov. 2000.
Paul et al, in Fundamental Immunology, Second edition Raven Press, p. 987-988, 1989.
Boon et al, Ann. Rev. Immunol. 24: 175-208, 2006.
An et al., “A recombinant minigene vaccine containing a nonameric cytotoxic-T-Lymphocyte epitope confers limited protection againstListeria monocytogenesinfection.” Infect. Immun., May 1996, vol. 64, No. 5, pp. 1685-1693.
Bielecki et al., “Bacillus subtilisexpressing a haemolysin gene fromListeria monocytogenescan grow in mammalian cells”, Nature 1990 354:175-176.
Decatur A.L. et al., “A PEST-Like Sequence in Listeriolysin O Essential forListeria monocytogenesPathogenicity”, Science 2000 290:992-995.
Gentschev et al., “SalmonellaStrain Secreting Active Listeriolysin Changes Its Intracellular Localization”, Infect. Immun. 1995 63:4202-4205.
Ikonimidis et al., “Delivery of a Viral Antigen to the Class I Processing and Presentation Pathway byListeria monocytogenes”, J.Exp. Med. 1994 180:2209-2218.
Kaufman S.H. et al., “Impact of intracellular location of and antigen display by intracellular bacteria: implications for vaccine development”, J. Immunol. Lett. 1999 65(1-2):81-84.
Kocks et al., “L. monocytogenes-induced actin assembly requires the actA gene product”,. Cell., Feb. 1992, vol. 68, No. 3, pp. 521-531.
Lin et al., “Treatment of Established Tumors with a Novel Vaccine That Enhances Major Histocompatibility Class II Presentation of Tumor Antigen1”, Cancer Res. 1996 56:21-26.
Mengaud et al., “Expression inEscherichia coliand sequence analysis of the listeriolysin O determinant ofListeria monocytogenes”, Infect. Immun. Apr. 1988, vol. 56, No. 4, pp. 766-772.
Moriishi et al., Sequence analysis of the actA gene ofListeria monocytogenesisolated from human. Microbiol. Immunol. 1998, vol. 42, No. 2, pp. 129-132.
Pan et al., “Regression of Established Tumors in Mice Mediated by the Oral Administration of a RecombinantListeria monocytogenesvaccine1”, Cancer Res. 1995 55:4776-4779.
Realini et al., “Proposed roles in protein-protein association and presentation of peptides by MHC Class I receptors”, FEBS Lett. 1994 348:109-113.
Rechsteiner and Rogers, “PEST sequences and regulation by proteolysis”, TIBS 1996 21:267-271.
Sirard et al., “Intracytoplasmic delivery of Lidteriolysin O by a vaccinal strain ofBacillus anthracisinduces CD8-mediated protection againstListeria monocytogenes.” J Immunology. Nov. 1997, vol. 159, pp. 4435-4443.
Tanabe et al., “Induction of Protective T Cells againstListeria monocytogenesin Mice by Immunization with a Listeriolysin O-Negative Avirulent Strain of Bacteria and Liposome-Encapsulated Listeriolysin O”, Infect. Immun. 1999 67(2):568-575.
Verma et al., “Delivery of class I and class II MHC-restricted T-cell epitopes of listeriolysin ofListeria monocytogenesby attenuatedSalmonella”, Vaccine. Feb. 1995, vol. 13, No. 2, pp. 142-150.
Wu et al., “Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens”, Cancer Res. 1996 56:21-26.
An et al. (1996) “A recombinant minigene vaccine containing a nonameric cytoxic-T-Lymphocyte epitope confers limited protection againstListeria monocytogenesinfection”Infect. Immun64,(5):1685-1693.
Attwood, et al. (2000) “The Babel of Bioinformatics”Science290(5491):471-473.
Bielecki et al. (1990) “Bacillus subtilisexpressing a haemolysin gene fromListeria monocytogenescan grow in mammalian cells”Nature354:175-176.
Boon, et al. (2006) “Human T cell responses against melanoma”Annu Rev Immunol. 24:175-208.
Bourquin, et al. (2000) “Myelin oligodendrocyte glycoprotein-DNA vaccination induces antibody-mediated autoaggression in experimental autoimmune encephalomyelitis”Eur J Immunol30:3663-3671.
Darji, et al. (1997) “Oral somatic transgene vaccination using attenuatedS. typhimurium” Cell91:765-776.
Decatur, et al. (2000) “A PEST-like sequence in Listeriolysin O essential forListeria monocytogenespathogenicity”Science290(5493):992-995.
Finn, et al. (2003) “Cancer vaccines: between the idea and the reality”Nature Reviews Immunology3:630-641.
Gentschev et al. (1995) “Salmonellastrain secreting active Listeriolysin changes its intracellular localization”Infect. Immun. 63:4202-4205.
Guzman, et al. (1998) “AttenuatedListeria monocytogenescarrier strains can deliver an HIV-1 gp120 T helper epitope to MHC class II-restricted human CD4+ T cells”European Journal of Immunology28:1807-1814.
Ikonomidis, et al. (1994) “Delivery of a viral antigen to the class I processing and presentation oathway byListeria monocytogenes” Journal of Experimental Medicine180(6):2209-2218.
Jenson, et al. (1997) “RecombinantListeria monocytogenesas a live vaccine vehicle and a probe for studying cell-mediated immunity”Immunological Review158:147-157.
Kaufman, et al. (1999) “Impact of intracellular l
Gunn, III George Raymond
Paterson Yvonne
Peters Christian
Cohen Mark S.
Huynh Phuong
Pearl Cohen Zedek Latzer LLP
The Trustees of the University of Pennsylvania
LandOfFree
Composition and methods for enhancing immunogenecity of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and methods for enhancing immunogenecity of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and methods for enhancing immunogenecity of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4149171